Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment

Neuropsychopharmacology

Volumn 15, Issue 4, 1996, Pages 395-405

  Meltzer, Herbert Y ^a,b   Cola, Philip A ^a   Parsa, Mahmoud ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Clozapine; Creatine kinase; Risperidone; Schiophrenia; Serotonin

Indexed keywords

CLOZAPINE; CREATINE KINASE; HALOPERIDOL; LOXAPINE; MELPERONE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOGLOBINURIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; RHABDOMYOLYSIS;

EID: 0030272215     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00276-J     Document Type: Article

References (70)

1. Bengzon A, Hippius H, Kanig K (1966): Some changes in the serum during treatment with psychotropic drugs. J Nerv Ment Dis 143:369-376
2. Bjerkenstedt L (1989): Melperone in the treatment of schizophrenia. Acta Psychiatr Scand 352(Suppl):35-39
3. Briscoe JG, Curry SC, Gerkin RD, Ruiz RR (1988): Pemoline-induced choreoathetosis and rhabdomyolysis. Med Toxicol Adverse Drug Exp 3:72-76
4. Cavanaugh JJ, Finlayson RE (1984): Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Clin Psychiatry 45:356-357
5. ®). Acta Psychiatr Scand 352(Suppl):7-15
6. Cogen FK, Rigg G, Simmons JL, Domino EF (1978): Phencyclidine-associated acute rhabdomyolysis. Ann Intern Med 88:210-212
7. Coryell W, Norby LH, Cohen LH (1978): Psychosis-induced rhabdomyolysis. Lancet 2:381-382
8. Das Gupta K, Young A (1991): Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52:105-107
9. Egan MF, Abi-Dargham A, Kirch DG, Wyatt RJ (1993): Serum creatine phosphokinase elevations in patients with tardive dyskinesia. Brit J Psychiatry 162:551-553
10. Endicott J, Spitzer RL (1978): A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844
11. Forrest AR, Galloway JH, March ID, Strachan GA, Clark JC (1994): A fatal overdose with 3,4-methylenedioxyamphetamine derivates. Forensic Sci Int 64:57-59
12. Foster FG, Kupfer DJ (1973); Psychomotor activity and serum creatine phosphokinase activity. Arch Gen Psychiatry 29:752-758
13. Goates MG, Escobar JI (1992): An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: Report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol 12:139-140
14. Goode DJ, Meltzer HY (1976): Effects of isometric exercise on serum creatine phosphokinase activity. Arch Gen Psychiatry 33:1207-1211
15. Goode DJ, Weinberg DH, Mazura TA, Curtis G, Moretti RJ, Meltzer HY (1977): Effect of limb restraints on serum creatine phosphokinase activity in normal volunteers. Biol Psychiatry 12:743-755
16. Grossman RA, Hamilton RW, Morse BM, Penn AS, Goldberg M (1974): Nontraumatic rhabdomyolysis and acute renal failure. N Eng J Med 291:807-811
17. Gurrera RJ, Romero JA (1993): Enzyme elevation in the neuroleptic malignant syndrome. Biol Psychiatry 34:634-640
18. Hashimoto F, Sherman CB, Jeffery WH (1984): Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intern Med 144:629-630
19. Henry JA, Jeffreys KJ, Dawling S (1992): Toxicity and deaths from 3,4-methylenedixoymethamphetamine ("ecstasy"). Lancet 340:384-387
20. Johnson SB, Alvariz WA, Freinhar JP (1986): A case of massive rhabdomyolysis following molindone administration. J Clin Psychiatry 47:607-608
21. Kellam AMP (1987): The neuroleptic-malignant syndrome, so-called: A Survey of the world literature. Brit J Psychiatry 150:752-759
22. Keshavan MS, Stecker J, Kambhapatio RK (1993): Creatine kinase elevations with clozapine. Brit J Psychiatry 64:118-120
23. Kirson JI, McQuistion HL, Pierce DW (1995): Severe elevations in serum creatine kinase associated with clozapine. J Clin Psychopharmacol 15:287-288
24. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988): Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
25. 2 receptors induces malignant hyperthermia. Naunyn-Schmiedeberg's Arch Pharmacol 341:483-493
26. Lui WY (1979): Phenothiazine-induced dystonia associated with an increase in serum creatine phosphokinase. Archives of Disease in Childhood 54:150-151
27. Malas KL, van Kammen DP (1982): Markedly elevated creatine phosphokinase levels after neuroleptic withdrawal. Am J Psych 139:231-232
28. Matcheri S, Stecker J, Kambhampati K (1994): Creatine kinase elevations with clozapine. Brit J Psychiatry 164:118-120
29. Meltzer HY (1968): Creatine kinase and aldolase in serum: Abnormality common to acute psychoses. Science 159: 1368-1370
30. Meltzer HY (1969): Muscle enzyme release in the acute psychoses. Arch Gen Psychiatry 21:102-112
31. Meltzer HY (1970): Increased activity of creatine phosphokinase and aldolase in the acute psychoses: Case reports. J Psychiatr Res 7:249-262
32. Meltzer HY (1971): Plasma creatine phosphokinase activity, hypothermia and stress. Am J Physiol 221:896-901
33. Meltzer HY (1973a): Creatine phosphokinase activity and clinical symptomatology: A study in acute schizophrenic patients. Arch Gen Psychiatry 29:589-593
34. Meltzer HY (1973b): Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia (Berlin) 29:337-346
35. Meltzer HY (1975): Neuromuscular abnormalities in the major mental illnesses. I. Serum enzyme studies. In Freedman DX (ed), Biology of the Major Psychoses. Research Publications Association of the Research in Nervous Mental Disorders, vol. 54. New York: Raven Press, pp 165-188
36. Meltzer HY (1976a): Neuromuscular dysfunction in schizophrenia. Schizophr Bull 2:106-135
37. Meltzer HY (1976b): Skeletal muscle necrosis following membrane-activity drugs plus serotonin. J Neurol Sci 28:41-56
38. Meltzer HY (1992): Treatment of the neuroleptic non-responsive schizophrenic patients. Schizophr Bull 18:515-542
39. Meltzer HY, Crayton JW (1974): Muscle abnormalities in psychotic patients. II. Serum CPK activity fiber abnormalities and branching and sprouting of subterminal nerves. Biol Psychiatry 8:191-208
40. Meltzer HY, Holy PA (1974): Black-white differences in serum creatine phosphokinase (CPK) activity. Clin Chim Acta 54:215-224
41. Meltzer HY, Moline R (1970a): Plasma enzymatic activity after exercise. Study of psychiatric patients and their relatives. Arch Gen Psychiatry 22:390-397
42. Meltzer HY, Moline R (1970b): Muscle abnormalities in acute psychoses. Arch Gen Psychiatry 23:481-491
43. Meltzer HY, Mrozak S, Boyer M (1970): Effects of intramuscular injections on serum creatine phosphokinase activity. Am J Med Sci 259:42-48
44. Meltzer HY, Ross-Stanton J, Schlessinger S (1980): Mean serum creatine kinase activity in patients with functional psychoses. Arch Gen Psychiatry 37:650-655
45. i values. J Pharmacol Exp Ther 251:238-246
46. Meltzer HY, Alphs LD, Bastini B, Ramirez L (1990): Effect of melperone in treatment-resistant schizophrenia. In Stefanis CN, Soldatos CR, Rabavilas AD (eds), Psychiatry Today Accomplishments and Promises, VIII World Congress of Psychiatry Abstracts. New York: Excerpta Medica International Congress Series 899, p 502
47. Merigian KS, Roberts JR (1987): Cocaine intoxication: Hyperpyrexia, rhabdomyolysis and acute renal failure. J Toxiol Clin Toxicol 25:135-148
48. Miller DD, Sharafuddin MJA, Kathol RG (1991): A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52:99-101
49. Moore NA, Tye NC, Axton MS, Risius FC (1992): The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
50. 125]iodopindolol as probes of sarcolemmal receptor function and specificity. J Biol Chem 258:12499-12508
51. Narukami H, Yoshioka K, Zhao J, Miike T (1991): Experimental serotonin myopathy as an animal model of muscle degeneration and regeneration in muscular dystrophy. Acta Neuropathol Berlin 81:510-516
52. Nomopolous P, Flaum M, Miller DD (1990): Atypical neuroleptic malignant syndrome (NMS) with an atypical neuroleptic: Clozapine-induced NMS without rigidity. Ann Clin Psychiatry 2:251-253
53. Pagala M, Amaladevi B, Azad D, Pagala S, Herzlich B, Namba T, Grob D (1993): Effect of cocaine on leakage of creatine kinase from isolated fast and slow muscles of rat. Life Sci 52:751-756
54. Parsa MA, Rohr T, Ramirez LF, Meltzer HY (1990): Neuroleptic malignant syndrome without neuroleptics. J Clin Psychopharmacol 10:437-438
55. Pearlman CA (1986): Neuroleptic-malignant syndrome: A review of the literature. J Clin Psychopharmacol 6:257-273
56. Pearlman CA, Wheadon P, Epstein S (1981): Creatine kinase elevation after neuroleptic treatment. Am J Psychiatry 145:1018-1019
57. Pope HG, Keck PE, McElroy SL (1986): Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143:1227-1233
58. 2 receptor antagonists on central sympathetic outflow and blood pressure in anaesthetised cats. Naunyn-Schmiedeberg's Arch Pharmacol 338:601-607
59. Ravi SD, Borge GF, Roach FL (1982): Neuroleptics, laryngealpharyngeal dystonia, and acute renal failure. J Clin Psychiatry 43:300
60. 2 dopamine receptor blockade. J Pharmacol Exp Ther 253:1162-1170
61. Stahl SM, Meltzer HY (1977): Serotonin accumulation by skeletal muscle. Exp Neurol 54:42-53
62. 2 receptors. J Pharmacol Exp Ther 266: 1374-1384
63. Taylor JR, Abichandani L (1980): Creatine phosphokinase elevations and psychiatric symptomatology. Biol Psychiatry 15:865-780
64. Tehan B, Hardern R, Bodenham A (1993): Hyperthermia associated with 3,4-methylenedioxy-ethamphetamine ("Eve"). Leeds General Infirmary 48:507-510
65. Terada Y, Shinohara S, Matui N, Ida T (1988): Amphetamine-induced myoglobinuric acute renal failure. Jap J Med 27:305-308
66. Thornberg SA, Ereshefsky L (1993): Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 13:510-514
67. Tsoi WF, Candilish JK, Kua EH (1985): Creatine phosphokinase and schizophrenia in Singapore. Ann Acad Med Singapore 14:84-86
68. 2 receptor antagonist ketanserin. Arch Int Pharmacodyn Ther 270:280-298
69. Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH (1993): Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 48:1057-1060
70. Yuen EC, Mobley WC (1995): Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves. Molec Med Today 1:278-286